Biomarker composition for diagnosis of degenerative brain disease
AssigneeAjou University Industry-Academic Cooperation Foundation
InventorSun Ah PARK
Life of this patent
Estimating the term…
Abstract
A biomarker composition for diagnosing degenerative brain diseases comprises TB (TRAF-6 binding) domain in SQSTM1/p62 protein. The TB (TRAF-6 binding) domain in the SQSTM1/p62 protein directly binds to the tau protein to remove the tau protein, and thus the exposure of the TB domain may be usefully utilized in diagnosing and/or treating degenerative brain diseases in degenerative brain diseases in which tauopathy is observed.
Claims9
A biomarker composition for diagnosing degenerative brain diseases comprising TB (TRAF-6 binding) domain in SQSTM1/p62 protein.
A kit for diagnosing degenerative brain diseases comprising an agent capable of measuring exposure level of TB (TRAF-6 binding) domain in SQSTM1/p62 protein.
A method of providing information necessary for diagnosing degenerative brain diseases comprising:
- (a) measuring an exposure level of TB (TRAF-6 binding) domain in tertiary structure of SQSTM1/p62 protein in a sample isolated from a patient;
- (b) comparing the exposure level of the TB domain with a control sample;
- and
- (c) determining as degenerative brain disease when the exposure level of the TB domain is lower than that of the control sample.
A method of screening a therapeutic agent for degenerative brain diseases comprising:
- (a) treating a candidate drug to a sample isolated from a patient;
- (b) measuring an exposure level of TB (TRAF-6 binding) domain in tertiary structure of SQSTM1/p62 protein before and after treatment with the candidate drug;
- and
- (c) selecting a candidate drug that increases the exposure level of the TB domain compared to a control sample.
Dependencies are inferred from the claim text.